At a glance

Most Recent Events

04 Dec 2017
According to a Sanofi Genzyme media release, based on the data from LIBERTY AD studies including SOLO 1, SOLO 2 and CHRONOS the Health Canada has approved Dupixen (dupilumab) for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

28 Sep 2017
According to a Sanofi and Regeneron Pharmaceuticals media release, based on the data from LIBERTY AD studies including SOLO 1, SOLO 2, CHRONOS, SOLO-CONTINUE and CAFE the European Commission has granted marketing authorization for Dupixent (dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.

21 Jul 2017
According to a Sanofi and Regeneron Pharmaceuticals Inc media release, based on the data from SOLO 1, SOLO 2, SOLO-CONTINUE, CHRONOS and CAFE studies the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Dupixent (dupilumab), for use in adults with moderate-to-severe atopic dermatitis.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription